Trump’s tariffs are set to impact all sectors in some capacity, including clinical trials.
With the US President placing a 10% levy on imports from China, this will have a significant impact on the cost of drugs, especially generics, which are set to soar. Tariffs could also lead to shortages of generics in the US, many of which are used as active controls in trials.
Go deeper with GlobalData
The Clinical Trials Arena team spoke to Doug Drysdale, CEO of Cybin, a biotech developing psychedelics, and Anshul Mangal, president of Project Farma, a consulting firm for biomanufacturing strategy and execution, to discuss the impacts expected in the sector.
You can listen to the podcast here:
